Healthcare -
Medical - Diagnostics & Research - NASDAQ - US
$ 3.39
6.27 %
$ 124 M
Market Cap
-3.42
P/E
1. INTRINSIC VALUE
Balance Sheet
Sera Prognostics, Inc.
| Current Assets | 47.6 M |
| Cash & Short-Term Investments | 46.2 M |
| Receivables | 53 K |
| Other Current Assets | 1.31 M |
| Non-Current Assets | 25 M |
| Long-Term Investments | 0 |
| PP&E | 1.24 M |
| Other Non-Current Assets | 23.7 M |
| Current Liabilities | 24.8 M |
| Accounts Payable | 1.97 M |
| Short-Term Debt | 194 K |
| Other Current Liabilities | 22.6 M |
| Non-Current Liabilities | 2 K |
| Long-Term Debt | 2 K |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Sera Prognostics, Inc.
| Revenue | 77 K |
| Cost Of Revenue | 82 K |
| Gross Profit | -5 K |
| Operating Expenses | 36.6 M |
| Operating Income | -36.6 M |
| Other Expenses | -3.74 M |
| Net Income | -32.9 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Sera Prognostics, Inc.
| Net Income | -32.9 M |
| Depreciation & Amortization | 833 K |
| Capital Expenditures | -56 K |
| Stock-Based Compensation | 7.01 M |
| Change in Working Capital | 11.3 M |
| Others | -1.01 M |
| Free Cash Flow | -14.2 M |
Wall Street Analysts Price Targets
Sera Prognostics, Inc.
SERA has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
SERA does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Sera Prognostics, Inc.
Sold
0-3 MONTHS
420 K USD 7
3-6 MONTHS
1.14 M USD 8
6-9 MONTHS
516 K USD 7
9-12 MONTHS
707 K USD 6
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Sera Prognostics Inc (SERA) Q4 2024 Earnings Call Transcript
Sera Prognostics Inc (NASDAQ:SERA ) Q4 2024 Earnings Conference Call March 19, 2025 5:00 PM ET Company Participants Peter DeNardo - IR, CapComm Partners Evguenia Lindgardt - President, CEO & Director Austin Aerts - CFO Conference Call Participants Dan Brennan - TD Cowen Margarate Boeye - William Blair Operator Good afternoon, and welcome to the Sera Prognostics Conference Call to review Fourth Quarter Fiscal Year 2024 Results. At this time, all participants are in listen-only mode.
seekingalpha.com
- 1 month ago
Sera Prognostics, Inc. (SERA) Reports Q4 Loss, Misses Revenue Estimates
Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.25 per share a year ago.
zacks.com
- 1 month ago
SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN
SALT LAKE CITY , March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as part of the Board's ongoing efforts to refresh its composition, expertise and experience.
prnewswire.com
- 1 month ago
SERA PROGNOSTICS REPORTS FOURTH QUARTER 2024 FINANCIAL RESULTS
SALT LAKE CITY , March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights: On January 6, 2025, the Society for Maternal Fetal Medicine ("SMFM") published an abstract reporting topline results for Sera's Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs ("PRIME") study.
prnewswire.com
- 1 month ago
Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2024 Financial Results on March 19, 2025
SALT LAKE CITY , March 11, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, March 19, 2025, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m.
prnewswire.com
- 1 month ago
Sera Prognostics To Present at TD Cowen 45th Annual Health Care Conference
SALT LAKE CITY , Feb. 21, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, from 9:50 a.m. – 10:20 a.m.
prnewswire.com
- 1 month ago
Sera Prognostics Announces Pricing of $50 Million Public Offering
SALT LAKE CITY , Feb. 10, 2025 /PRNewswire/ -- Sera Prognostics, Inc., The Pregnancy Company® ("Sera" or the "Company") (Nasdaq: SERA), which focuses on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the pricing of its underwritten public offering of 1,250,000 shares of its Class A common stock at a public offering price of $4.00 per share, and, in lieu of Class A common stock to certain investors, pre-funded warrants to purchase 11,250,000 shares of its Class A common stock at a public offering price of $3.9999 per pre-funded warrant, which equals the public offering price per share of the Class A common stock less the $0.0001 per share exercise price of each pre-funded warrant, in each case before underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Sera, are expected to be approximately $50 million.
prnewswire.com
- 2 months ago
Sera Prognostics Announces Proposed Public Offering
SALT LAKE CITY , Feb. 10, 2025 /PRNewswire/ -- Sera Prognostics, Inc., The Pregnancy Company® ("Sera" or the "Company") (Nasdaq: SERA), which focuses on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it has commenced a proposed underwritten public offering of its Class A common stock and, in lieu of Class A common stock to certain investors, pre-funded warrants to purchase shares of its Class A common stock. In addition, Sera intends to grant the underwriters a 30-day option to purchase shares of Class A common stock in an amount up to an additional 15% of the total amount of shares of Class A common stock and shares of Class A common stock underlying pre-funded warrants sold in the public offering on the same terms and conditions.
prnewswire.com
- 2 months ago
Sera Prognostics to Host Virtual R&D Day on January 31
Event will showcase results of Company's pivotal PRIME study and include the principal investigator SALT LAKE CITY , Jan. 27, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it plans to host a virtual R&D day on January 31, 2025, from 5:00 to 6:00 p.m. ET/2:00 to 3:00 p.m.
prnewswire.com
- 2 months ago
Sera Prognostics to Present at 43rd Annual J.P. Morgan Healthcare Conference
SALT LAKE CITY , Jan. 6, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference taking place January 13-16, 2025 in San Francisco.
prnewswire.com
- 3 months ago
Sera Prognostics to Present PRIME Study Results at 2025 SMFM Pregnancy Meeting
SALT LAKE CITY , Dec. 4, 2024 /PRNewswire/ -- Sera Prognostics, Inc. , The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the results of the PRIME study were accepted as a late-breaking abstract for oral podium presentation at the Society for Maternal-Fetal Medicine 2025 Pregnancy Meeting™ on January 31, 2025 at 10:15 a.m. MT . Dr. Brian Iriye – maternal-fetal medicine expert at the High Risk Pregnancy Center in Las Vegas, Nevada, and principal investigator for the PRIME study – will present the results of the full PRIME study.
prnewswire.com
- 4 months ago
Sera Prognostics to Present at Piper Sandler 36th Annual Healthcare Conference
SALT LAKE CITY , Dec. 2, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the Piper Sandler 36th Annual Healthcare Conference on December 5, 2024 at 2:30 p.m. ET. Zhenya Lindgardt, President and CEO, will participate in a fireside chat and provide a company update and discuss Sera's latest achievements.
prnewswire.com
- 4 months ago
8. Profile
Summary
Sera Prognostics, Inc. SERA
COUNTRY
US
INDUSTRY
Medical - Diagnostics & Research
MARKET CAP
$ 124 M
Dividend Yield
0.00%
Description
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Contact
2749 East Parleys Way, Salt Lake City, UT, 84109
https://seraprognostics.com
IPO
Date
July 15, 2021
Employees
63
Officers
Dr. John J. Boniface Ph.D.
Chief Scientific Officer
Dr. Gregory C. Critchfield M.D., M.S.
Executive Director
Ms. Evguenia Lindgardt M.B.A.
President, Chief Executive Officer & Director
Mr. Austin Aerts
Chief Financial Officer
Mr. Benjamin G. Jackson J.D.
General Counsel
Mr. Robert G. Harrison
Chief Information Officer
Dr. Paul Kearney Ph.D.
Chief Data Officer